Status:
COMPLETED
Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease
Lead Sponsor:
KVT-Study Group
Collaborating Sponsors:
Tokai University
Yokohama City University
Conditions:
Chronic Kidney Disease
Hypertension
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to prove the hypothesis that the progression of renal and cardiovascular disease is more efficiently prevented when the angiotensin II receptor blocker valsartan is added ...
Detailed Description
It is widely recognized that suppression of the renin-angiotensin system ameliorates progression of chronic kidney disease (CKD) and that CKD is an important risk factor for development of cardiovascu...
Eligibility Criteria
Inclusion
- CKD with serum creatinine more than 2.0 mg/dl
- Blood pressure more than 130/85 mmHg
- 20 years old or above
Exclusion
- End-stage renal disease with maintenance dialysis
- Polycystic kidney disease
- Collagen disease
- Malignant or accelerated hypertension
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
312 Patients enrolled
Trial Details
Trial ID
NCT00190580
Start Date
February 1 2003
End Date
April 1 2008
Last Update
March 31 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Marianna University School of Medicine
Kawasaki, Kanagawa, Japan, 216-8511